Am­gen may be way late to the obe­si­ty game, but the mar­ket scouts are lov­ing the block­buster po­ten­tial of AMG 133

Am­gen has been dan­gling an­oth­er snap­shot of ear­ly-stage da­ta from its obe­si­ty drug AMG 133. And the an­a­lysts have been grab­bing it and beg­ging for more.

Cowen’s Yaron Wer­ber re­minds us in a note that Am­gen got the process start­ed with their busi­ness re­view for the an­ti-GIPR/GLP-1 pep­tide con­ju­gate back in Feb­ru­ary. Then dur­ing an up­date for their AHA ses­sion, Am­gen ex­ecs not­ed more dos­ing and “a 7.19-14.52% re­duc­tion in body weight (low vs high dose) by 12 weeks of treat­ment. Man­age­ment con­firmed the da­ta is from on-treat­ment pa­tients (which is no­table as ITT obe­si­ty pa­tients have his­tor­i­cal­ly shown 1-2% low­er re­sponse), though dropouts were not high in the study thus far.”

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA